Product Description
Cocaine is a benzoid acid ester that that was originally used as a local anesthetic, but is no longer used because of its potent addictive qualities. When given in high doses systemically, cocaine has mood elevating effects that have led to its widescale abuse. High doses of cocaine can be associated with toxic reactions including hyperthermia, rhabdomyolysis, shock and acute liver injury which can be severe and even fatal. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Cocaine)
Mechanisms of Action: Sodium Channel Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous, Topical, Nasal
FDA Designation: *
Approval Status: Approved
Approved Countries: Canada | Hong Kong | Russia | Spain | Taiwan | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Lannett
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Anesthesia Related|Cocaine-Related Disorders
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04792034 |
RA-VP-000-357 | P3 |
Recruiting |
Cocaine-Related Disorders|Anesthesia Related |
2027-12-01 |
5% |
2025-12-27 |
Primary Completion Date|Primary Endpoints|Start Date |
NCT06273540 |
STA-P7-C001 | P1 |
Completed |
Cocaine-Related Disorders |
2024-10-07 |
66% |
2024-11-28 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/02/2026 |
News Article |
Intelligent Bio Solutions Announces Closing of $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules |
|
12/31/2025 |
News Article |
Intelligent Bio Solutions Announces New Manufacturing Partnership to Strengthen Global Production Capability and Increase Margins |
|
12/31/2025 |
News Article |
Intelligent Bio Solutions Announces $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules |
|
12/24/2025 |
News Article |
FDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMA |